Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome Patients with Rare Autosomal Dominant Disease

On April 27, 2026 — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, announced that CEO Raza Bokhari, MD, MBA, along with the Medicus leadership team, conducted a series of meetings on Capitol Hill with senior lawmakers across key healthcare committees to advance support for:
- Orphan Drug Designation for SkinJect® for Gorlin Syndrome
- Registrational Investigation New Drug (IND) approval for Gorlin Syndrome patients
- Rare disease pediatric FDA voucher program
These engagements included:
- Brett Guthrie — Chair of the House Energy & Commerce Committee, which has primary jurisdiction over U.S. healthcare policy
- John Joyce — Member, House Energy & Commerce Committee; Co-Chair, Congressional Skin Cancer Caucus
- Diana Harshbarger — Vice Chair, House Energy & Commerce Subcommittee on Health
- Gus Bilirakis — Co-Chair, Congressional Rare Disease Caucus; Senior Member, Energy & Commerce Committee
These meetings reflect coordinated outreach to leadership directly involved in shaping U.S. healthcare legislation and rare disease policy.
In collaboration with the Gorlin Syndrome Alliance, discussions emphasized the urgent need for new treatment approaches, as patients with Gorlin syndrome often experience lifelong recurrence of basal cell carcinomas and are frequently described as “never cancer free,” highlighting the need for non-surgical therapeutic options such as SkinJect®.
“Our engagement with policymakers reflects a clear alignment around accelerating access to innovative therapies for patients with significant unmet need,” said Dr. Bokhari, Executive Chairman & CEO of Medicus, “We believe SkinJect® has the potential to shift the treatment paradigm in Gorlin Syndrome by offering a localized, repeatable, non-surgical approach.”
The Company is concurrently advancing regulatory and clinical planning to support a registrational development pathway for SkinJect®, with a focus on generating decision-grade data to enable expedited development in high-burden patient populations.
Addressing a High-Burden Rare Disease
Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare, inherited condition driven primarily by mutations in the PTCH1 gene, leading to dysregulation of the Hedgehog signaling pathway and early, recurrent tumor formation.
Patients with this condition may develop dozens to over 1,000 basal cell carcinomas over their lifetime, often beginning in childhood, requiring repeated surgical interventions that can result in significant physical and psychological burden.
Despite this high disease burden:
- There are no FDA-approved therapies specifically for BCC in Gorlin Syndrome
- Current treatments rely heavily on surgical excision or Mohs surgery
- Systemic therapies, such as Hedgehog inhibitors, are limited by tolerability and recurrence upon discontinuation
Medicus believes SkinJect® has the potential to address this gap through a localized, repeatable, non-surgical treatment approach.
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.
Company’s key therapeutics assets are:
SkinJect™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also called nevoid BCC syndrome, collectively representing a ~$2 billion market opportunity.
Teverelix®, a next-generation GnRH antagonist is a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, collectively representing a ~$6 billion market opportunity.
The Company is actively engaged in the following collaborations:
Skinject™ Platform Expansion
In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed, and there can be no assurance that such definitive agreements will be executed.
The Company is exploring co-development of thermostable infectious disease vaccines combining HelixNano’s proprietary mRNA technology with the Medicus microneedle array delivery platform.
Patient Access and Advocacy
In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.
In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect™, the Company’s investigational D-MNAs, under physician supervision.
AI Enabled Clinical Development
In December 2025, the Company signed a non-binding letter of intent to collaborate with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences, to develop an AI-driven clinical data analytics platform to support capital-efficient and time-efficient clinical development through data-driven dynamic clinical-site selection, pharmacodynamic (PD) informed patient stratification, and enrollment forecasting. The initial phase of the collaboration is expected to support the upcoming Teverelix clinical study planned for 2026. There can be no assurance that a definitive agreement will be executed or that the proposed collaboration will proceed as contemplated.
